121 related articles for article (PubMed ID: 38460248)
21. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
23. The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0.
Cui Y; Liu X; Li S; Wang H; Xiang Y; Zhang Y; Song M; Geng J; Liu Z; Teng H; Zhu X; Cai Y; Li Y; Wang W
Clin Transl Oncol; 2024 Apr; 26(4):1012-1021. PubMed ID: 38051436
[TBL] [Abstract][Full Text] [Related]
24. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
25. The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Cui J; Yang L; Guo L; Shao Y; Tan D; Li N; Zhang H
Oncotarget; 2017 Jun; 8(23):37845-37854. PubMed ID: 28103579
[TBL] [Abstract][Full Text] [Related]
26. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
27. Lymph Node Regression to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: Prognostic Implication and a Predictive Model.
Sun Y; Wu X; Lin H; Lu X; Huang Y; Chi P
J Gastrointest Surg; 2021 Apr; 25(4):1019-1028. PubMed ID: 32219686
[TBL] [Abstract][Full Text] [Related]
28. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
30. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
33. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
34. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
36. Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
Gao X; Wang C; Yu Y; Singh D; Yang L; Zhou Z
World J Surg Oncol; 2020 Nov; 18(1):304. PubMed ID: 33228677
[TBL] [Abstract][Full Text] [Related]
37. Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients.
Mei SW; Liu Z; Wei FZ; Chen JN; Wang ZJ; Shen HY; Li J; Zhao FQ; Pei W; Wang Z; Wang XS; Liu Q
World J Gastroenterol; 2020 Aug; 26(31):4624-4638. PubMed ID: 32884221
[TBL] [Abstract][Full Text] [Related]
38. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM).
Capelli G; De Simone I; Spolverato G; Cinquini M; Moschetti I; Lonardi S; Masi G; Carlomagno C; Corsi D; Luppi G; Gambacorta MA; Valvo F; Cannizzaro R; Grillo F; Barbaro B; Restivo A; Messina M; Pastorino A; Aschele C; Pucciarelli S
J Gastrointest Surg; 2020 Sep; 24(9):2150-2159. PubMed ID: 32394125
[TBL] [Abstract][Full Text] [Related]
39. Predictive Value of the Neutrophil-Lymphocyte Ratio for Tumor Regression Grade and Prognosis of Local Advanced Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
Li S; Wang D; Wei R; Yu G; Wang X; Jiang Z
Technol Cancer Res Treat; 2023; 22():15330338231202611. PubMed ID: 37807729
[TBL] [Abstract][Full Text] [Related]
40. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
